INTERNATIONAL JOURNAL OF HEALTH RESEARCH AND DEVELOPMENT (IJHRD)
EFFECTS OF PARICALCITOL ON BODY COMPOSITION IN VITAMIN D-DEFICIENT RATS
E-ISSN: 7883-6773
P-ISSN: 3457-2861
DOI: https://iigdpublishers.com/article/102
Paricalcitol has been proposed for the treatment of secondary hyperparathyroidism in patients with renal failure and vitamin D deficiency (VDD); however, VDD is related to a range of clinical complaints. We aimed to investigate the effects of paricalcitol on body composition in VDD rats. Thirty adult male rats aged 10 weeks were randomly divided into three groups of 10, comprising control, VDD, and VDD plus paricalcitol32) ng/rat intraperitoneal injection) (VDD+P), at the Animal Lab of the Endocrinology and Metabolism Research Center, Shiraz, Iran, in 2020. Body composition was assessed after three weeks via serum biochemical tests and dual-energy X-ray absorptiometry. Finally, the data were analyzed by using the paired sample t test, the one-way ANOVA, and the Tukey post hoc test.
Global lean mass and fat mass were lower in the VDD and VDD+P groups than in the controls (P<0.001). Global fat percentage was reduced significantly in the VDD+P group (P=0.029). Paricalcitol reduced global fat mass and fat percentage in a rat model with VDD. Evaluation of insulin and adiponectin levels is suggested to clarify the physiology of paricalcitol in VDD states.
Farhad Koohpeyma
Felsenfeld AJ. (1997). Considerations for the treatment of secondary hyperparathyroidism in renal failure. J Am Soc Nephrol.;8:993- 1004. PubMed PMID: 9189868.
Mucsi I, Hercz G. (1999). Relative hypoparathy- roidism and adynamic bone disease. Am J Med Sci.;317:405-9. doi: 10.1097/00000441-199906000-00009. PubMed PMID: 10372841.
Coyne DW, Andress DL, Amdahl MJ, Ritz E, de Zeeuw D. (2013). Effects of paricalcitol on cal- cium and phosphate metabolism and mark- ers of bone health in patients with diabetic nephropathy: results of the VITAL study. Nephrol Dial Transplant.;28:2260-8. doi: 10.1093/ndt/gft227. PubMed PMID: 23787544; PubMed Central PMCID: PMCPMC3769981.
Tonbul HZ, Solak Y, Atalay H, Turkmen K, Altintepe L. (2012). Efficacy and tolerability of intravenous paricalcitol in calcitriol-resist- ant hemodialysis patients with secondary hyperparathyroidism: 12-month prospec- tive study. Ren Fail.;34:297-303. doi: 10.3109/0886022X.2011.647298. PubMed PMID: 22251408.
Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, et al. (2008). Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodi- alysis or peritoneal dialysis. Am J Nephrol.;28:97-106. doi: 10.1159/000109398. PubMed PMID: 17914251.
